Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.
作者信息
Sukari Ammar, Nagasaka Misako, Diab Maria, Al Sibai Khaled, Atassi Bassel, Elayoubi Jailan A, Kim Seongho, Küçük Ömer
机构信息
Department of Oncology, Barbara Ann Karmanos Comprehensive Cancer Institute, Detroit, Michigan.
Department of Advanced Medical Innovation, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
出版信息
Clin Otolaryngol. 2019 Jul;44(4):639-643. doi: 10.1111/coa.13316. Epub 2019 Apr 1.
Abstract
摘要
相似文献
1
Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.西妥昔单抗与甲氨蝶呤治疗复发或转移性头颈部鳞状细胞癌——单机构54例患者分析
Clin Otolaryngol. 2019 Jul;44(4):639-643. doi: 10.1111/coa.13316. Epub 2019 Apr 1.
2
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.接受西妥昔单抗和化疗治疗的复发性或转移性头颈癌患者的预后评分
PLoS One. 2017 Jul 7;12(7):e0180995. doi: 10.1371/journal.pone.0180995. eCollection 2017.
3
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.复发性/转移性头颈部鳞状细胞癌（R/M HNSCC）的EXTREME方案：单机构队列中的治疗结果
Acta Oncol. 2015 Jul;54(7):1071-5. doi: 10.3109/0284186X.2014.964308. Epub 2014 Oct 24.
4
Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.在一线化疗后，每两周给予维持剂量西妥昔单抗治疗复发性或转移性头颈部鳞状细胞癌的安全性和可行性。
Head Neck. 2013 Oct;35(10):1471-4. doi: 10.1002/hed.23170. Epub 2012 Oct 6.
5
Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.西妥昔单抗联合化疗治疗复发和转移性头颈癌的疗效与毒性：一项前瞻性观察研究。
Indian J Cancer. 2016 Oct-Dec;53(4):487-492. doi: 10.4103/ijc.IJC_7_17.
6
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.丙戊酸联合顺铂和西妥昔单抗治疗复发和/或转移性头颈部鳞状细胞癌的II期临床研究-V-CHANCE试验
BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y.
7
Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.西妥昔单抗为基础的治疗在复发性/转移性头颈部鳞状细胞癌：在咀嚼槟榔流行的地区的经验。
J Chin Med Assoc. 2010 Jun;73(6):292-9. doi: 10.1016/S1726-4901(10)70064-2.
8
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.在不适合顺铂联合治疗的复发或转移性（R/M）头颈部鳞状细胞癌（SCCHN）人群中，作为一线治疗，甲氨蝶呤联合或不联合西妥昔单抗，一项 Ib 期随机 II 期研究开始。
Head Neck. 2020 May;42(5):828-838. doi: 10.1002/hed.26053. Epub 2020 Jan 6.
9
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer.采用改良 TPEx 作为复发和/或转移性头颈部癌症的一线治疗方法。
Anticancer Res. 2021 Apr;41(4):2045-2051. doi: 10.21873/anticanres.14973.
10
Afatinib in squamous cell carcinoma of the head and neck.阿法替尼治疗头颈部鳞状细胞癌。
Expert Opin Pharmacother. 2016 Jun;17(9):1295-301. doi: 10.1080/14656566.2016.1183647. Epub 2016 May 19.
引用本文的文献
1
Clinical landscape for patients with head and neck cancers enrolled in phase I trials at a tertiary referral center.在一家三级转诊中心参加I期试验的头颈癌患者的临床概况。
Ther Adv Med Oncol. 2025 Jun 30;17:17588359251337244. doi: 10.1177/17588359251337244. eCollection 2025.
2
Combination Therapy as a Promising Way to Fight Oral Cancer.联合治疗作为对抗口腔癌的一种有前景的方法。
Pharmaceutics. 2023 Jun 4;15(6):1653. doi: 10.3390/pharmaceutics15061653.
3
Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.针对移动和隐藏目标的射击——头颈部鳞状细胞癌中的肿瘤细胞可塑性与Notch信号通路
Cancers (Basel). 2021 Dec 10;13(24):6219. doi: 10.3390/cancers13246219.
本文引用的文献
1
Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.接受 PD1 抑制剂治疗后进展后序贯紫杉醇治疗的患者的反应。
Oral Oncol. 2018 May;80:100-102. doi: 10.1016/j.oraloncology.2018.03.011. Epub 2018 Mar 28.
2
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.帕博利珠单抗治疗铂类和西妥昔单抗难治性头颈癌：一项单臂II期研究的结果
J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.
3
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
4
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.每周紫杉醇联合西妥昔单抗治疗预处理后的复发性/转移性头颈部癌患者的疗效和安全性。
Oral Oncol. 2013 Feb;49(2):182-5. doi: 10.1016/j.oraloncology.2012.09.003. Epub 2012 Sep 28.
5
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.头颈部复发和/或转移性鳞状细胞癌患者一线治疗中厄洛替尼联合每周紫杉醇的 II 期研究。
Ann Oncol. 2012 Apr;23(4):1016-22. doi: 10.1093/annonc/mdr367. Epub 2011 Aug 23.
6
Platinum-based chemotherapy plus cetuximab in head and neck cancer.铂类化疗联合西妥昔单抗治疗头颈癌。
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
7
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.西妥昔单抗在先前铂类疗法失败的复发性和/或转移性头颈部鳞状细胞癌患者中的疗效概述。
Cancer. 2008 Jun 15;112(12):2710-9. doi: 10.1002/cncr.23442.
8
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.一项开放标签、非对照、多中心II期研究，旨在评估西妥昔单抗单药治疗对铂类治疗无效的复发和/或转移性头颈部鳞状细胞癌患者的疗效和毒性。
J Clin Oncol. 2007 Jun 1;25(16):2171-7. doi: 10.1200/JCO.2006.06.7447.
9
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.顺铂加氟尿嘧啶与卡铂加氟尿嘧啶对比甲氨蝶呤治疗晚期头颈部鳞状细胞癌的随机对照研究：西南肿瘤协作组研究
J Clin Oncol. 1992 Aug;10(8):1245-51. doi: 10.1200/JCO.1992.10.8.1245.
Zotero 插件